Suppr超能文献

科斯特洛综合征的基因型-表型相关性:43例患者的HRAS突变分析

Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases.

作者信息

Kerr B, Delrue M-A, Sigaudy S, Perveen R, Marche M, Burgelin I, Stef M, Tang B, Eden O B, O'Sullivan J, De Sandre-Giovannoli A, Reardon W, Brewer C, Bennett C, Quarell O, M'Cann E, Donnai D, Stewart F, Hennekam R, Cavé H, Verloes A, Philip N, Lacombe D, Levy N, Arveiler B, Black G

机构信息

Regional Genetic Service, Central Manchester University Hospital NHS Trust, Manchester, UK.

出版信息

J Med Genet. 2006 May;43(5):401-5. doi: 10.1136/jmg.2005.040352. Epub 2006 Jan 27.

Abstract

BACKGROUND

Costello syndrome (CS) is a rare multiple congenital abnormality syndrome, associated with failure to thrive and developmental delay. One of the more distinctive features in childhood is the development of facial warts, often nasolabial and in other moist body surfaces. Individuals with CS have an increased risk of malignancy, suggested to be about 17%. Recently, mutations in the HRAS gene on chromosome 11p13.3 have been found to cause CS.

METHODS

We report here the results of HRAS analysis in 43 individuals with a clinical diagnosis of CS.

RESULTS

Mutations were found in 37 (86%) of patients. Analysis of parental DNA samples was possible in 16 cases for both parents and in three cases for one parent, and confirmed the mutations as de novo in all of these cases. Three novel mutations (G12C, G12E, and K117R) were found in five cases.

CONCLUSIONS

These results confirm that CS is caused, in most cases, by heterozygous missense mutations in the proto-oncogene HRAS. Analysis of the major phenotypic features by mutation suggests a potential correlation between malignancy risk and genotype, which is highest for patients with an uncommon (G12A) substitution. These results confirm that mutation testing for HRAS is a reliable diagnostic test for CS.

摘要

背景

科斯特洛综合征(CS)是一种罕见的多发性先天性异常综合征,与生长发育迟缓有关。儿童期较为独特的特征之一是面部疣的出现,常见于鼻唇沟及其他身体潮湿部位。CS患者患恶性肿瘤的风险增加,据推测约为17%。最近发现,位于11号染色体p13.3上的HRAS基因突变会导致CS。

方法

我们在此报告对43例临床诊断为CS的个体进行HRAS分析的结果。

结果

37例(86%)患者发现有突变。16例可对父母双方的DNA样本进行分析,3例可对一方父母的样本进行分析,所有这些病例均证实突变为新发突变。5例患者发现了3种新突变(G12C、G12E和K117R)。

结论

这些结果证实,在大多数情况下,CS是由原癌基因HRAS的杂合错义突变引起的。通过突变分析主要表型特征表明,恶性肿瘤风险与基因型之间可能存在相关性,对于具有罕见(G12A)替代的患者,这种相关性最高。这些结果证实,HRAS突变检测是CS的可靠诊断方法。

相似文献

1
Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases.
J Med Genet. 2006 May;43(5):401-5. doi: 10.1136/jmg.2005.040352. Epub 2006 Jan 27.
5
Two cases with severe lethal course of Costello syndrome associated with HRAS p.G12C and p.G12D.
Eur J Med Genet. 2012 Nov;55(11):615-9. doi: 10.1016/j.ejmg.2012.07.007. Epub 2012 Aug 7.
6
Severe neonatal manifestations of Costello syndrome.
J Med Genet. 2008 Mar;45(3):167-71. doi: 10.1136/jmg.2007.054411. Epub 2007 Nov 26.
8
HRAS and the Costello syndrome.
Clin Genet. 2007 Feb;71(2):101-8. doi: 10.1111/j.1399-0004.2007.00743.x.
9
Clinical and molecular analysis of RASopathies in a group of Turkish patients.
Clin Genet. 2013 Feb;83(2):181-6. doi: 10.1111/j.1399-0004.2012.01875.x. Epub 2012 Apr 9.

引用本文的文献

2
Monogenic etiologies of persistent human papillomavirus infections: A comprehensive systematic review.
Genet Med. 2024 Feb;26(2):101028. doi: 10.1016/j.gim.2023.101028. Epub 2023 Nov 14.
3
Lysines K117 and K147 play conserved roles in Ras activation from Drosophila to mammals.
G3 (Bethesda). 2023 Nov 1;13(11). doi: 10.1093/g3journal/jkad201.
5
Syndromic forms of congenital hyperinsulinism.
Front Endocrinol (Lausanne). 2023 Mar 30;14:1013874. doi: 10.3389/fendo.2023.1013874. eCollection 2023.
6
Cancer in Costello syndrome: a systematic review and meta-analysis.
Br J Cancer. 2023 Jun;128(11):2089-2096. doi: 10.1038/s41416-023-02229-7. Epub 2023 Mar 25.
7
Increased osteoclastogenesis contributes to bone loss in the Costello syndrome mouse model.
Front Cell Dev Biol. 2022 Oct 18;10:1000575. doi: 10.3389/fcell.2022.1000575. eCollection 2022.
8
Inside the Noonan "universe": Literature review on growth, GH/IGF axis and rhGH treatment: Facts and concerns.
Front Endocrinol (Lausanne). 2022 Aug 18;13:951331. doi: 10.3389/fendo.2022.951331. eCollection 2022.
9
Multidisciplinary Management of Costello Syndrome: Current Perspectives.
J Multidiscip Healthc. 2022 Jun 2;15:1277-1296. doi: 10.2147/JMDH.S291757. eCollection 2022.

本文引用的文献

1
HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation.
Am J Med Genet A. 2006 Jan 1;140(1):1-7. doi: 10.1002/ajmg.a.31047.
2
Germline mutations in HRAS proto-oncogene cause Costello syndrome.
Nat Genet. 2005 Oct;37(10):1038-40. doi: 10.1038/ng1641. Epub 2005 Sep 18.
3
The adult phenotype in Costello syndrome.
Am J Med Genet A. 2005 Jul 15;136(2):128-35. doi: 10.1002/ajmg.a.30747.
4
Disruption of the PDGFB gene in a 1;22 translocation patient does not cause Costello syndrome.
Genomics. 2004 May;83(5):883-92. doi: 10.1016/j.ygeno.2003.10.012.
5
Costello syndrome and neurological abnormalities.
Am J Med Genet A. 2003 Dec 15;123A(3):301-5. doi: 10.1002/ajmg.a.20330.
7
Further delineation of cardiac abnormalities in Costello syndrome.
Am J Med Genet. 2002 Aug 1;111(2):115-29. doi: 10.1002/ajmg.10558.
8
Recurrent transitional cell carcinoma in a child with the Costello syndrome.
J Urol. 2002 Sep;168(3):1133-4. doi: 10.1016/S0022-5347(05)64609-5.
10
Second case of bladder carcinoma in a patient with Costello syndrome.
Am J Med Genet. 2000 Jan 31;90(3):256-9. doi: 10.1002/(sici)1096-8628(20000131)90:3<256::aid-ajmg16>3.0.co;2-d.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验